Lite Strategy Inc
LITS
Company Profile
Business description
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
Contact
9920 Pacific Heights Boulevard
Suite 150
San DiegoCA92121
USAT: +1 858 369-7100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
4
Stocks News & Analysis
stocks
Beaten down real estate share receives legal blow
Real estate share remains cheap despite losing airport legal battle.
stocks
OpenAI joins the mega-AI lab IPO race, but timing is uncertain
The ChatGPT maker joined Anthropic in filing a confidential S-1 with the SEC, teeing up a future IPO.
stocks
What happens if Tesla and SpaceX merge?
We see a solid business case for a merger, but not without hurdles, including Tesla shareholders’ concern about SpaceX’s valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.10 | 29.10 | 0.32% |
| CAC 40 | 8,309.03 | 108.24 | 1.32% |
| DAX 40 | 24,455.24 | 245.53 | 1.01% |
| Dow JONES (US) | 50,862.66 | 13.91 | 0.03% |
| FTSE 100 | 10,412.92 | 109.04 | 1.06% |
| HKSE | 24,718.10 | 468.81 | 1.93% |
| NASDAQ | 25,624.46 | 185.20 | -0.72% |
| Nikkei 225 | 66,020.04 | 1,802.77 | 2.81% |
| NZX 50 Index | 13,393.87 | 191.71 | 1.45% |
| S&P 500 | 7,370.15 | 24.15 | -0.33% |
| S&P/ASX 200 | 8,804.00 | 30.50 | 0.35% |
| SSE Composite Index | 4,031.51 | 44.50 | 1.12% |